The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Association NewsFull Access

APA's Minority Fellowships Program Invites Applicants

Published Online:https://doi.org/10.1176/pn.40.22.0008a

Psychiatry residents are invited to apply for APA's Minority Fellowships Program (MFP). The MFP provides educational opportunities not only to minority residents, but to all residents interested in providing quality and effective service to minorities and the underserved. The fellowships provide the funds necessary for psychiatry residents to experience a specialized educational program specifically geared toward building leaders in psychiatry. It is also designed to involve fellows in APA's work and give APA the perspective of young psychiatrists.

The MFP fellows are classified into three groups: APA/SAMHSA Fellows (funded by the Substance Abuse and Mental Health Services Administration), APA/SAMHSA Substance Abuse Fellows (funded by the Centers for Substance Abuse Treatment and Substance Abuse Prevention), and APA/AstraZeneca Fellows (funded by AstraZeneca).

SAMHSA and substance abuse fellows receive a fellowship stipend for twelve months based on their postgraduate year and availability of federal funds. AstraZeneca fellows do not receive a stipend; however, travel funds are available to attend specific APA meetings and special projects. AstraZeneca fellows serve for two years.

All applicants must be in their PGY-2 year by July 2006 or PGY-5 year for the substance abuse segment and must be APA members. SAMHSA applicants must be U.S. citizens or permanent residents at the time of application. AstraZeneca applicants need not be U.S. citizens or permanent residents or graduates of a U.S. medical school. Residents interested in the substance abuse segment must be in an addiction training program approved by the affiliated medical school or agency where a significant number of substance abuse patients are from minority and underserved groups.

The deadline for applications is January 31, 2006. More information is available by contacting Marilyn King by phone at (703) 907-8653 or by e-mail or online at<www.psych.org/edu/other_res/apa—fellowship/cmhs_index.cfm.